TFRC and cancer: Uptake assay confirmed the magnetic nanocarrier’s ability to preferentially accumulate into MCF7 cancer cells versus NHDF (non-tumoral cells), in agreement with the fact that the TfR1 is overexpressed in a cancer cell.